Idecabtagene vicleucel

From WikiMD.org
Jump to navigation Jump to search

Idecabtagene vicleucel (pronounced as i-dek-ab-TAG-e-ne vik-LOO-sel) is a type of immunotherapy used in the treatment of multiple myeloma, a type of cancer that forms in a type of white blood cell called a plasma cell.

Etymology

The name "Idecabtagene vicleucel" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature. The "ide-" prefix refers to the immune effector function, "cabta-" refers to the target antigen, and "-gene vicleucel" refers to the genetic modification of the T cells.

Usage

Idecabtagene vicleucel is used for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

Mechanism of Action

Idecabtagene vicleucel is a chimeric antigen receptor (CAR) T cell therapy. It works by modifying the patient's T cells to express a CAR that targets the B cell maturation antigen (BCMA), a protein that is nearly universally expressed on cancer cells in multiple myeloma.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski